Alphatec (ATEC) Stock Price, News & Analysis

Company Overview

Alphatec Holdings, Inc. (NASDAQ: ATEC) is a medical technology company focused on improving the surgical treatment of spinal disorders. The company develops and commercializes products designed to support spine surgery, including implants, biologics, surgical instruments and related technologies.

Its portfolio is intended for procedures addressing conditions such as spinal deformities, degenerative disc disease and other disorders affecting the spine. Alphatec emphasizes surgeon-focused solutions and integrated technologies that support preoperative planning, intraoperative decision-making and the placement of spinal implants.

Headquartered in Carlsbad, California, Alphatec serves hospitals, surgeons and other healthcare providers in the United States and select international markets. The company’s products are marketed through direct sales and distribution channels, with its business centered on advancing surgical techniques and expanding the use of its spine-focused systems.

Key Stats

• Today's Range: $10.39 to $11.03
• 50-Day Range: $8.06 to $10.58
• 52-Week Range: $6.82 to $23.29
• Volume: 4.17 million shs
• Average Volume: 2.99 million shs
• Market Capitalization: $1.68 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.40
• Consensus Rating: Moderate Buy

Alphatec Stock Analysis - MarketRank™

Alphatec scored higher than 84% of companies evaluated by MarketBeat, and ranked 90th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alphatec has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Alphatec has a consensus price target of $17.40, representing about 61.3% upside from its current price of $10.79.

Amount of Analyst Coverage

Alphatec has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alphatec are expected to grow in the coming year, from ($0.45) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alphatec is -15.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alphatec is -15.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alphatec has a P/B Ratio of 134.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.23% of the float of Alphatec has been sold short.

Short Interest Ratio / Days to Cover

Alphatec has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Alphatec has recently increased by 0.31%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alphatec does not currently pay a dividend.

Dividend Growth

Alphatec does not have a long track record of dividend growth.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.15

News Sentiment

Alphatec has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Alphatec this week, compared to 6 articles on an average week.

Search Interest

16 people have searched for ATEC on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.

MarketBeat Follows

1 people have added Alphatec to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $934,329.00 in company stock, which represents 0.0561% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Alphatec insiders have bought 1,185.38% more of their company's stock than they have sold. Specifically, they have bought $1,013,150.00 in company stock and sold $78,821.00 in company stock.

Percentage Held by Insiders

13.48% of the stock of Alphatec is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.35% of the stock of Alphatec is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ATEC
• CIK: 1350653
• Web: www.atecspine.com
• Phone: (760) 431-9286
• Fax: 800-922-1356
• Employees: 913
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Alphatec: $17.40
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +60.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$143.36 million
• Net Margins: -13.49%
• Pretax Margin: -13.46%
• Return on Equity: -6,752.24%
• Return on Assets: -13.88%

Debt

• Debt-to-Equity Ratio: 40.35
• Current Ratio: 1.89
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $764.16 million
• Price / Sales: 2.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 135.75

Miscellaneous

• Outstanding Shares: 154,450,000
• Free Float: 133,631,000
• Market Cap: $1.68 billion
• Optionable: Optionable
• Beta: 0.85